NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Biotechnology

Healthcare
$19.74 +0.39%

+$0.12 today

Market cap
$2.37B
Beta
0.08
P/E (TTM)
-17.2
EPS (TTM)
-$1.76
52W Low $17.63High $42.21

Volume 1.80M

Average 1.21M

NAMS Net Income

Bottom-line profit, the starting point for calculating cash from operations.

NewAmsterdam Pharma Company N.V.NASDAQ: NAMS

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income growth accelerates

Q2 FY2026 net income of $64.14M (cash outflow) rose 269.4% year over year, ahead of the -10.7% change in trailing-twelve-month net income. Sequentially, it rose 32.4% from the prior quarter. Over 3 fiscal years it compounded at +108.0% a year.

Context

  • Net income amounted to 905.7% of revenue in FY2025, up 375.5 pp from a year earlier.
  • Net income grew in size in 2 of the last 3 fiscal years.

What to watch

Whether net income reaches the consensus estimate from 10 analysts of -$185.78M (-8.9%) for the fiscal year ending Dec 2026, a step up from the -15.6% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
-$64.14M+32.4% QoQ
Last fiscal yearDec 2025
-$203.82M-15.6% YoY
LTMJun 2026
-$147.97M-10.7% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+269.4%-248.2%-517.5 pp
1 year-15.6%-8.9%+6.8 pp
3-year CAGR+108.0%-11.0%-119.0 pp
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
(203.82M) USD
Year-over-year change
+15.6%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How NAMS compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -10.7% is the 8th highest of 9, against a peer median of +8.0%.
  • Net income amounts to 2078.0% of revenue for NAMS, versus a peer median of 223.4%.
NAMS Competitors
Net Income for NAMS and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VKTXViking Therapeutics, Inc.LTM Jun 2026$534.8M USD+211.7%+73.5%—
DNLIDenali Therapeutics Inc.LTM Jun 2026$511.45M USD+6.8%+16.3%14191.2%
MDGLMadrigal Pharmaceuticals, Inc.LTM Jun 2026$325.1M USD+15.3%-0.8%25.3%
AMLXAmylyx Pharmaceuticals, Inc.LTM Sep 2026$163.2M USD+9.3%-10.0%—
NAMSNewAmsterdam Pharma Company N.V.LTM Jun 2026$147.97M USD-10.7%+108.0%2078.0%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$113.28M USD-2.6%+41.5%—
BIOABioAge Labs, Inc.LTM Mar 2026$89.93M USD+26.6%+26.6%871.8%
SEPNSepterna, Inc.LTM Sep 2026$59M USD+0.3%+20.9%61.3%
ATHEAlterity Therapeutics LimitedFY2025A$12.15M AUD-36.5%-1.8%223.4%
Peer median (excluding NAMS) —+8.0%+18.6%223.4%

Competitors are the stored peer set for NAMS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(41.79M)(22.63M)(176.94M)(241.6M)(203.82M)
Depreciation & Amortization5K9K49K113K220K
Deferred Income Tax00000
Stock-Based Compensation1.24M4.12M24.57M33.62M59.43M
Change in Working Capital4.47M10.37M5.87M(32.67M)(7.94M)
Accounts Receivables0(4.18M)4.03M0(13.28M)
Inventory00000
Accounts Payables6.56M4.81M5.07M(12.95M)4.91M
Other Working Capital(2.09M)9.75M(3.23M)(19.73M)427K
Other Non-Cash Items6.55M18.8M5.23M81.98M4.34M
Operating Cash Flow(29.51M)10.67M(141.22M)(158.56M)(147.78M)
Capital Expenditures(24K)(221K)(24K)(672K)(246K)
Acquisitions (Net)00000
Purchases of Investments000(62.18M)(296.73M)
Sales of Investments0000122.06M
Other Investing Activities00000
Investing Cash Flow(24K)(221K)(24K)(62.85M)(174.92M)
Debt Repayment0747K000
Common Stock Issued84.7M396.95M8.91M645.51M29.52M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities0(5.79M)014M0
Financing Cash Flow84.7M391.91M8.91M659.51M29.52M
Effect of Forex Changes(4.68M)5.25M5.05M(6.8M)12.76M
Net Change in Cash50.49M407.6M(127.28M)431.29M(280.42M)
Free Cash Flow(29.54M)10.44M(141.24M)(159.24M)(148.03M)

NewAmsterdam Pharma Company N.V.

NASDAQ:NAMS

Intrinsic Alpha fair value

Locked

Current Price

$19.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.